Study models
Recent Advances in AI & Multi-Omics for Translational Research
AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction
Terray Therapeutics Unveils EMMI: AI-Driven Platform Revolutionizes Small Molecule Drug Discovery
Terray Therapeutics; EMMI; generative AI; small molecule drug discovery; AI-native platform; chemical space; drug optimization; biotech; machine learning; COATI model
Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025
Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology
Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector
Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
Hospital Group Seeks to Intervene in Lawsuit Against Lilly’s 340B Rebate Model
340B Drug Pricing Program, Eli Lilly, rebate model, lawsuit, hospital intervention, Health Resources and Services Administration (HRSA), drug pricing
Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models
Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models
Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology
Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.
Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models
340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation
AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics
AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition